Targeted sequencing of Plasma from patient BMBC1 using the IMPACT targeted sequencing platform
Targeted sequencing was performed using the Integrated Mutation Profiling of Actionable Cancer Targeted (IMPACT) platform targeting all exons of 341 cancer genes shown to harbor actionable mutations. 40-450ng of DNA was used to prepare barcoded sequence libraries (New England Biolabs, Kapa Biosystems), which were pooled at equimolar concentrations for hybridization exon capture (Nimblegen SeqCap).
BMBC1_plasma_IMPACT